Comparative Analysis of Treatment Outcomes in Endometrial Cancer: Hormonal Therapy vs. Chemotherapy in Postmenopausal Women

Marriam Zeb; Hina Nisar Ahmed Memon; Habibah Nadeem; Rabia Altaf; Khalida Bano; Najaf Abbas Ghafoor

doi:10.70749/ijbr.v3i5.1490

Authors

Marriam Zeb Department of Radiotherapy, Jinnah Hospital, Lahore, Pakistan
Hina Nisar Ahmed Memon Ward 9 A, Jinnah Post Graduate Medical Centre, Karachi, Pakistan
Habibah Nadeem Pharmacology and Therapeutics, CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan
Rabia Altaf School of Pharmacy, University of Management and Technology (UMT), Lahore, Pakistan
Khalida Bano Department of Biochemistry, Jhalawan Medical College Khuzdar, Khuzdar, Balochistan, Pakistan
Najaf Abbas Ghafoor Department of Physiology, Sir Syed College of Medical Sciences, Karachi, Pakistan

DOI:

https://doi.org/10.70749/ijbr.v3i5.1490

Keywords:

Endometrial Cancer, Postmenopausal Women, Hormonal Therapy, Chemotherapy, Quality of Life, Adverse Events, Regression Analysis, T-Test Analysis, Patient-Centered Care

Abstract

Hormonal and chemotherapy therapies were studied in postmenopausal women using a quantitative study. Because hormones play a role in endometrial cancer, this research worked to close a major gap in patient management. Total of 250 patients were randomly selected from oncology centers within the given geographic area. After patients had finished their treatment, the team surveyed them to find any improvements to their health and any changes from using the drugs. To analyze carefully what affects quality of life, regression analysis was applied, Chi-Square analysis examined relationships between the treatments and side effects and an independent sample t-test was used to compare average quality of life scores between the groups. Upon completing the regression analysis, the results showed that treatment type, patient age, how advanced the tumor was and the number of health problems determined a person’s quality of life, with chemotherapy being much less favorable than hormonal therapy. The analysis found that side effects from chemotherapy were more common than those from radiation. Patients in the hormonal therapy group reported a better quality of life than patients treated with chemotherapy. In agreement with earlier studies, they advise that researchers developing postmenopausal treatments should weigh how much women may gain from the medication against the possible side effects. Based on the study, doctors should use a strategy that combines information about the disease, the patient’s health problems and their well-being. The results of future qualitative and long-term studies can clarify patient preferences, their long-term outcomes and the impact of various therapies. The research finds it important to give women who are postmenopausal supportive, effective and tailored treatment for endometrial cancer

Downloads

Download data is not yet available.

References

Londero, A.P., et al., Hormone replacement therapy in endometrial cancer survivors: a meta-analysis. Journal of Clinical Medicine, 2021. 10(14): p. 3165.

https://doi.org/10.3390/jcm10143165

Chlebowski, R.T., et al., Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women's Health Initiative randomized trials. Journal of Clinical Oncology, 2024. 42(30): p. 3537-3549.

https://doi.org/10.1200/jco.23.01918

Cagnacci, A. and A.P. Londero, Hormone therapy in endometrial cancer survivors: Time for a change. 2022, Taylor & Francis. p. 795-796.

https://doi.org/10.1080/09513590.2022.2128105

Suzuki, Y., et al., Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer. Gynecologic Oncology, 2024. 180: p. 14-23.

https://doi.org/10.1016/j.ygyno.2023.11.010

Kelkar, S.S., et al., Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States. Gynecologic Oncology Reports, 2022. 42: p. 101026.

https://doi.org/10.1016/j.gore.2022.101026

Wagner, V.M. and F.J. Backes, Do not forget about hormonal therapy for recurrent endometrial cancer: a review of options, updates, and new combinations. Cancers, 2023. 15(6): p. 1799.

https://doi.org/10.3390/cancers15061799

Madsen, T.E., et al., A review of hormone and non-hormonal therapy options for the treatment of menopause. International journal of women's health, 2023: p. 825-836.

https://doi.org/10.2147/ijwh.s379808

Zhang, G.-Q., et al., Menopausal hormone therapy and women’s health: An umbrella review. PLoS Medicine, 2021. 18(8): p. e1003731.

https://doi.org/10.1371/journal.pmed.1003731

Mahdi, H., et al., Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option? International Journal of Gynecological Cancer, 2023. 33(11): p. 1675-1681.

https://doi.org/10.1136/ijgc-2023-004454

Garg, V., A.S. Jayaraj, and L. Kumar, Novel approaches for treatment of endometrial carcinoma. Current Problems in Cancer, 2022. 46(5): p. 100895.

https://doi.org/10.1016/j.currproblcancer.2022.100895

Lee, W.-L., et al., Hormone therapy for patients with advanced or recurrent endometrial cancer. Journal of the Chinese Medical Association, 2014. 77(5): p. 221-226.

https://doi.org/10.1016/j.jcma.2014.02.007

Felix, A.S., et al., Menopausal hormone therapy and mortality among endometrial cancer patients in the NIH-AARP Diet and Health Study. Cancer Causes & Control, 2015. 26: p. 1055-1063.

https://doi.org/10.1007/s10552-015-0598-0

Bestvina, C.M. and G.F. Fleming, Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. The oncologist, 2016. 21(10): p. 1250-1259.

https://doi.org/10.1634/theoncologist.2016-0062

Lim, S., et al., The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients. Journal of Gynecologic Oncology, 2018. 29(5).

https://doi.org/10.3802/jgo.2018.29.e72

Passarello, K., S. Kurian, and V. Villanueva. Endometrial cancer: an overview of pathophysiology, management, and care. in Seminars in oncology nursing. 2019. Elsevier.

https://doi.org/10.1016/j.soncn.2019.02.002

Guidozzi, F., Estrogen therapy in gynecological cancer survivors. Climacteric, 2013. 16(6): p. 611-617.

https://doi.org/10.3109/13697137.2013.806471

Leslie, K.K., et al., Endometrial cancer. Obstetrics and Gynecology Clinics, 2012. 39(2): p. 255-268.

https://doi.org/10.1016/j.ogc.2012.04.001

Musa, F.B., et al., State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025. Current Opinion in Obstetrics and Gynecology, 2025. 37(2): p. 111-119.

https://doi.org/10.1097/gco.0000000000001008

Crean-Tate, K.K., et al., Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. American journal of obstetrics and gynecology, 2020. 222(2): p. 103-113.

https://doi.org/10.1016/j.ajog.2019.08.043

Jerzak, K.J., L. Duska, and H.J. MacKay, Endocrine therapy in endometrial cancer: An old dog with new tricks. Gynecologic oncology, 2019. 153(1): p. 175-183.

https://doi.org/10.1016/j.ygyno.2018.12.018

Chiofalo, B., et al., Hysteroscopic evaluation of endometrial changes in breast cancer women with or without hormone therapies: results from a large multicenter cohort study. Journal of Minimally Invasive Gynecology, 2020. 27(4): p. 832-839.

https://doi.org/10.1016/j.jmig.2019.08.007

Dizon, D.S., Treatment options for advanced endometrial carcinoma. Gynecologic oncology, 2010. 117(2): p. 373-381.

https://doi.org/10.1016/j.ygyno.2010.02.007

Cheng, J.M., et al., Case report: prolonged durable clinical benefit and low toxicity from combination endocrine therapy in a patient with recurrent endometrial carcinoma. Frontiers in Oncology, 2023. 13: p. 1249370.

https://doi.org/10.3389/fonc.2023.1249370

Londero, A.P., et al., Quantification of women who could benefit from hormone therapy after endometrial cancer treatment: an analysis of SEER Data. Current Oncology, 2022. 29(12): p. 9215-9223.

https://doi.org/10.3390/curroncol29120721

Kinyanjui, R.M., Clinicopathological Characteristics, Management and Outcomes of Endometrial Cancer at Kenyatta National Hospital, 2014-2022. 2024, University of Nairobi.

Ghumman, S., Fertility and Assisted Reproductive Technology in Cancer Survivors: Endometrial Cancer. Fertility & ART in Medical Disorders, 2023: p. 46.

Alhusaini, H., et al., Adult-type ovarian granulosa cell tumour: treatment outcomes from a single-institution experience. Cureus, 2022. 14(11).

https://doi.org/10.7759/cureus.31045

Fife, A.J., et al., Reduced healthcare access contributes to delay of care in endometrial cancer. Gynecologic Oncology, 2024. 182: p. 115-120.

https://doi.org/10.1016/j.ygyno.2024.01.010

Paleari, L., et al., Exploring the Prognostic and Predictive Roles of Ki-67 in Endometrial Cancer. International Journal of Translational Medicine, 2023. 3(4): p. 479-486.

https://doi.org/10.3390/ijtm3040033

Luyendijk, M., et al., Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer. PharmacoEconomics, 2023. 41(8): p. 981-997.

https://doi.org/10.1007/s40273-023-01277-4